Aytu BioScience, Inc., a specialty healthcare company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and ZolpiMist, an oral spray for the treatment of insomnia. It also offers MiOXSYS, an in vitro diagnostic semen analysis test that is used in the measurement of static oxidation reduction potential in human semen. In addition, the company provides MiOXSYS analyzer, a portable lightweight desktop platform that is used in clinical or research laboratory or near a patient care area; and MiOXSYS disposable sensors. The company is based in Englewood, Colorado.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone720-437-6580
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.66 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/13/2019 (Estimated)
OptionableNot Optionable
Aytu Bioscience (NASDAQ:AYTU) Frequently Asked Questions
What is Aytu Bioscience's stock symbol?
Aytu Bioscience trades on the NASDAQ under the ticker symbol "AYTU."
When did Aytu Bioscience's stock split? How did Aytu Bioscience's stock split work?
Aytu Bioscience's stock reverse split on Tuesday, August 29th 2017. The 1-20 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 28th 2017. An investor that had 100 shares of Aytu Bioscience stock prior to the reverse split would have 5 shares after the split.
How were Aytu Bioscience's earnings last quarter?
Aytu Bioscience Inc (NASDAQ:AYTU) issued its quarterly earnings data on Thursday, February, 7th. The company reported ($0.72) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.35) by $0.37. The business had revenue of $1.80 million for the quarter, compared to analyst estimates of $1.58 million. Aytu Bioscience had a negative net margin of 217.45% and a negative return on equity of 95.52%. View Aytu Bioscience's Earnings History.
When is Aytu Bioscience's next earnings date?
What price target have analysts set for AYTU?
1 brokers have issued 12 month price targets for Aytu Bioscience's stock. Their forecasts range from $10.00 to $10.00. On average, they expect Aytu Bioscience's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 446.4% from the stock's current price. View Analyst Price Targets for Aytu Bioscience.
What is the consensus analysts' recommendation for Aytu Bioscience?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aytu Bioscience in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aytu Bioscience.
What are Wall Street analysts saying about Aytu Bioscience stock?
Here are some recent quotes from research analysts about Aytu Bioscience stock:
- 1. According to Zacks Investment Research, "Aytu BioScience, Inc. is a healthcare company which focused on commercialization of novel products in the field of urology. The company's marketed products consists of ProstaScint(R), Primsol(R) and MiOXSYS(TM) which addresses prostate cancer, urinary tract infections, male infertility and male sexual dysfunction. Aytu BioScience, Inc. is based in Englewood, Colorado. " (4/11/2019)
- 2. Northland Securities analysts commented, "We believe the P4 study will position Natesto® as the only TRT treatment that does NOT impair male fertility. This will provide Natesto® with further meaningful clinical differentiation, in addition to its lacking a Black Box warning relating to transference carried by existing TRT topical treatments. Pre-open, Aytu BioScience provided an enrollment update regarding its ongoing Phase 4 spermatogenesis study evaluating the affect of Natesto® on sperm production in men with hypogonadism, specifically evaluating sperm concentration, sperm motility, and total sperm count. To date, the Company has enrolled 56 in the study, exceeding its initial targeted enrollment of 40. The study is being conducted by Dr." (3/27/2019)
Has Aytu Bioscience been receiving favorable news coverage?
News coverage about AYTU stock has trended somewhat negative this week, InfoTrie reports. The research group scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Aytu Bioscience earned a news sentiment score of -1.6 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an effect on the company's share price in the near term.
Who are some of Aytu Bioscience's key competitors?
Some companies that are related to Aytu Bioscience include Checkpoint Therapeutics (CKPT), Processa Pharmaceuticals (PCSA), DURECT (DRRX), Catabasis Pharmaceuticals (CATB), Cumberland Pharmaceuticals (CPIX), Adamis Pharmaceuticals (ADMP), Sesen Bio (SESN), OASMIA PHARMACE/ADR (OASM), Nemus Bioscience (NMUS), Tiziana Life Sciences (TLSA), Infinity Pharmaceuticals (INFI), Otonomy (OTIC), Apricus Biosciences (APRI), Entasis Therapeutics (ETTX) and Sunesis Pharmaceuticals (SNSS).
What other stocks do shareholders of Aytu Bioscience own?
Who are Aytu Bioscience's key executives?
Aytu Bioscience's management team includes the folowing people:
- Mr. Joshua R. Disbrow, Chairman & CEO (Age 44)
- Mr. David A. Green, CFO, Sec. & Treasurer (Age 56)
- Mr. Jarrett T. Disbrow, Chief Operating Officer (Age 44)
Who are Aytu Bioscience's major shareholders?
Aytu Bioscience's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Virtu Financial LLC (0.14%). Company insiders that own Aytu Bioscience stock include David A Green and Jarrett Disbrow. View Institutional Ownership Trends for Aytu Bioscience.
Which institutional investors are buying Aytu Bioscience stock?
AYTU stock was bought by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Company insiders that have bought Aytu Bioscience stock in the last two years include David A Green and Jarrett Disbrow. View Insider Buying and Selling for Aytu Bioscience.
How do I buy shares of Aytu Bioscience?
Shares of AYTU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aytu Bioscience's stock price today?
One share of AYTU stock can currently be purchased for approximately $1.83.
How big of a company is Aytu Bioscience?
Aytu Bioscience has a market capitalization of $22.79 million and generates $3.66 million in revenue each year. The company earns $-10,180,000.00 in net income (profit) each year or ($27.94) on an earnings per share basis.
What is Aytu Bioscience's official website?
How can I contact Aytu Bioscience?
Aytu Bioscience's mailing address is 373 INVERNESS PARKWAY SUITE 206, ENGLEWOOD CO, 80112. The company can be reached via phone at 720-437-6580 or via email at [email protected]
MarketBeat Community Rating for Aytu Bioscience (NASDAQ AYTU)
MarketBeat's community ratings are surveys of what our community members think about Aytu Bioscience and other stocks. Vote "Outperform" if you believe AYTU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AYTU will underperform the S&P 500 over the long term. You may vote once every thirty days.
